Allegis Investment Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Allegis Investment Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	$1.26M	Buy	3,659 +8	+0.2%	+$2.78K	0.39%	63
2017 Q4	$1.37M	Buy	3,651 +489	+15%	+$198K	0.4%	69
2017 Q3	$1.41M	Buy	3,162 +181	+6%	+$86.1K	0.33%	84
2017 Q2	$1.46M	Buy	2,981 +963	+48%	+$421K	0.37%	84
2017 Q1	$782K	Buy	+2,018	New	+$748K	0.21%	119
2016 Q1	–	Sell	-14	Closed	-$8K	–	759
2015 Q4	$8K	Buy	+14	New	+$7.58K	﹤0.01%	737

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Allegis Investment Advisors's REGN Position: Q1 2018 in Review

Allegis Investment Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 0.22% in Q1 2018, buying an estimated $2.78K and bringing the position to 3,659 shares worth $1.26M. The position accounts for 0.39% of the portfolio, ranked #63.

Allegis Investment Advisors first reported a position in REGN in Q4 2015 and has held it in 6 quarters since. The position peaked at $1.46M in Q2 2017. 620 funds tracked by Wall St. Rank hold REGN as of Q1 2018.

Allegis Investment Advisors held 3,659 shares of Regeneron Pharmaceuticals worth $1.26M as of Q1 2018.
Allegis Investment Advisors bought 8 Regeneron Pharmaceuticals shares in Q1 2018, an estimated $2.78K.
Regeneron Pharmaceuticals made up 0.39% of Allegis Investment Advisors's portfolio in Q1 2018, its #63 holding.
Allegis Investment Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2015 and has held it in 6 quarters since.
Allegis Investment Advisors's Regeneron Pharmaceuticals position peaked at $1.46M in Q2 2017.
620 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2018.

Based on Allegis Investment Advisors's 13F filing for Q1 2018, filed 24 Apr 2018.